HAIC of FOLFOX

DRUG6 trials

Sponsors

Sun Yat-sen University, Beijing Tsinghua Chang Gung Hospital, Tianjin Medical University Cancer Institute and Hospital

Conditions

Cholangiocarcinoma, IntrahepaticHepatocellular CarcinomaHepatocellular Carcinoma (HCC)

Phase 2

Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE

WithdrawnNCT03722498

Sun Yat-sen UniversityHepatocellular Carcinoma

Start: 2018-06-01End: 2021-03-22Updated: 2023-07-11

Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC

Sun Yat-sen UniversityHepatocellular Carcinoma

Start: 2018-08-04End: 2019-09-01Target: 150Updated: 2019-04-17

FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma

RecruitingNCT07012798

Tianjin Medical University Cancer Institute and HospitalHepatocellular Carcinoma (HCC)

Start: 2025-09-25End: 2026-12-31Target: 30Updated: 2026-05-13

Phase 3

HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC

Sun Yat-sen UniversityHepatocellular Carcinoma

Start: 2018-03-09End: 2020-03-09Target: 300Updated: 2018-03-16

HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B

Sun Yat-sen UniversityHepatocellular Carcinoma

Start: 2018-10-01End: 2023-10-01Target: 304Updated: 2020-05-21

Phase 4

Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma

RecruitingNCT05124002

Beijing Tsinghua Chang Gung HospitalCholangiocarcinoma, Intrahepatic

Start: 2022-08-01End: 2026-04-01Target: 66Updated: 2024-03-04

Related Papers

Efficacy of oncolytic virus combined with HAIC of mFOLFOX for IMCC: A single-center, single-arm, prospective study.

Journal of Clinical Oncology2024-06-011 citations